EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vitro Metabolism and Transport Characteristics of Zastaprazan

Min Seo Lee iD, Jihoon Lee, Minyoung Pang iD, John Kim iD, Hyunju Cha, Banyoon Cheon, Min-Koo Choi, Im-Sook Song iD, Hye Suk Lee iD

Pharmaceutics · 13.06.2024 · 16 (6) · 799

DOI: 10.3390/pharmaceutics16060799 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 13.06.2024. Verfasst von Min Seo Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and BK21 Four-Sponsored Advanced Program for SmartPharma Leaders, The Catholic University of Korea, Bucheon 14662, Republic of Ko…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zastaprazan (JP-1366), a novel potassium-competitive acid blocker, is a new drug for the treatment of erosive esophagitis. JP-1366 is highly metabolized in human, mouse, and dog hepatocytes but moderately metabolized in rat and monkey hepatocytes when estimated from the metabolic stability of this compound in hepatocyte suspension and when 18 phase I metabolites and 5 phase II metabolites [i.e., N-dearylation (M6), hydroxylation (M1, M19, M21), dihydroxylation (M7, M8, M14, M22), trihydroxylation (M13, M18), hydroxylation and reduction (M20), dihydroxylation and reduction (M9, M16), hydrolysis (M23), hydroxylation and glucuronidation (M11, M15), hydroxylation and sulfation (M17), dihydroxylation and sulfation (M10, M12), N-dearylation and hydroxylation (M3, M4), N-dearylation and dihydroxylation (M5), and N-dearylation and trihydroxylation (M2)] were identified from JP-1366 incubation with the hepatocytes from humans, mice, rats, dogs, and monkeys. Based on the cytochrome P450 (CYP) screening test and immune-inhibition analysis with CYP antibodies, CYP3A4 and CYP3A5 played major roles in the metabolism of JP-1366 to M1, M3, M4, M6, M8, M9, M13, M14, M16, M18, M19, M21, and M22. CYP1A2, 2C8, 2C9, 2C19, and 2D6 played minor roles in the metabolism of JP-1366. UDP-glucuronosyltransferase (UGT) 2B7 and UGT2B17 were responsible for the glucuronidation of M1 to M15. However, JP-1366 and active metabolite M1 were not substrates for drug transporters such as organic cation transporter (OCT) 1/2, organic anion transporter (OAT) 1/3, organic anion transporting polypeptide (OATP)1B1/1B3, multidrug and toxic compound extrusion (MATE)1/2K, P-glycoprotein (P-gp), and breast cancer-resistant protein (BCRP). Only M1 showed substrate specificity for P-gp. The findings indicated that drug-metabolizing enzymes, particularly CYP3A4/3A5, may have a significant role in determining the pharmacokinetics of zastaprazan while drug transporters may only have a small impact on the absorption, distribution, and excretion of this compound.

Schlagwörter

Stichwörter der Autor:innen

drug transportersdrug-metabolizing enzymesmetabolite identificationpotassium-competitive acid blocker (P-CAB)zastaprazan (JP-1366)

Autor:innen und Institutionen

  • College of Pharmacy and BK21 Four-Sponsored Advanced Program for SmartPharma Leaders, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
  • BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, Vessel-Organ Interaction Research Center (VOICE), Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National Univers…
  • College of Pharmacy, Dankook University, Cheonan 30019, Republic of Korea.
  • Onconic Therapeutics Inc., Seoul 06236, Republic of Korea.

ORCID-Profile: Min Seo Lee, Minyoung Pang, John Kim, Im-Sook Song, Hye Suk Lee

Zitieren

APA

Lee, M. S., Lee, J., Pang, M., Kim, J., Cha, H., Cheon, B., Choi, M. K., Song, I. S., & Lee, H. S. (2024). In Vitro Metabolism and Transport Characteristics of Zastaprazan. Pharmaceutics, 16(6), 799. https://doi.org/10.3390/pharmaceutics16060799

Vancouver

Lee MS, Lee J, Pang M, Kim J, Cha H, Cheon B, et al. In Vitro Metabolism and Transport Characteristics of Zastaprazan. Pharmaceutics. 2024;16(6):799. doi:10.3390/pharmaceutics16060799

BibTeX
@article{Lee2024,
  author = {Lee, Min Seo and Lee, Jihoon and Pang, Minyoung and Kim, John and Cha, Hyunju and Cheon, Banyoon and Choi, Min-Koo and Song, Im-Sook and Lee, Hye Suk},
  title = {In Vitro Metabolism and Transport Characteristics of Zastaprazan},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {6},
  pages = {799},
  doi = {10.3390/pharmaceutics16060799}
}
Kostenlos starten →